Clinigen Licenses Commercialization Rights for Proleukin from Novartis in the US
Shots:
- Novartis to receive $210M as total deal value- including $120M upfront- $60M deferred payment for 12mos. and $30M milestone on sales of product. Clinigen to get commercialization rights for Novartis’ Proleukin in the US and WW license for Proleukin
- The focus of the agreement is to develop and commercialize Proleukin and strengthen Clinigen’s immune-oncology portfolio with expansion of footprints in the US
- Proleukin (aldesleukin- human recombinant IL-2) is a synthetic protein acts similarily as nterleukin-2 (IL-2) involved in activating WBCs and is being evaluated in 80 trials in the US for multiple therapy areas
Ref: Clinigen | Image: Pharmacy Research UK
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com